Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.

Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M.

Ann Oncol. 2012 Jan;23(1):59-64. doi: 10.1093/annonc/mdr052. Epub 2011 Apr 2.

PMID:
21460378
2.

2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.

De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J.

J Clin Oncol. 2004 Mar 15;22(6):1034-9.

PMID:
15020605
3.

Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.

De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C, Pont J.

J Clin Oncol. 2001 Sep 1;19(17):3740-4. Erratum in: J Clin Oncol 2001 Dec 1;19(23):4355.

PMID:
11533096
4.

False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.

Decoene J, Winter C, Albers P.

Urol Oncol. 2015 Jan;33(1):23.e15-23.e21. doi: 10.1016/j.urolonc.2014.09.019. Epub 2014 Nov 4.

PMID:
25454484
5.

FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.

Becherer A, De Santis M, Karanikas G, Szabó M, Bokemeyer C, Dohmen BM, Pont J, Dudczak R, Dittrich C, Kletter K.

Eur J Radiol. 2005 May;54(2):284-8.

PMID:
15837411
6.

The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.

Hinz S, Schrader M, Kempkensteffen C, Bares R, Brenner W, Krege S, Franzius C, Kliesch S, Heicappel R, Miller K, de Wit M.

J Urol. 2008 Mar;179(3):936-40; discussion 940. doi: 10.1016/j.juro.2007.10.054. Epub 2008 Jan 22.

PMID:
18207171
7.

Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.

Treglia G, Sadeghi R, Annunziata S, Caldarella C, Bertagna F, Giovanella L.

Biomed Res Int. 2014;2014:852681. doi: 10.1155/2014/852681. Epub 2014 May 15. Review.

8.

Can we rely on PET in the follow-up of advanced seminoma patients?

Siekiera J, Małkowski B, Jóźwicki W, Jasiński M, Wronczewski A, Pietrzak T, Chmielowska E, Petrus A, Kamecki K, Mikołajczak W, Kraśnicki K, Chłosta P, Drewa T.

Urol Int. 2012;88(4):405-9. doi: 10.1159/000337056. Epub 2012 Apr 12.

9.

[Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].

Müller J, Schrader AJ, Jentzmik F, Schrader M.

Urologe A. 2011 Mar;50(3):322-7. doi: 10.1007/s00120-010-2469-3. German.

PMID:
21161157
10.

Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.

Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA.

Br J Cancer. 2000 Oct;83(7):863-9.

11.

The role of 18F-FDG PET/CT in the management of testicular cancers.

Cook GJ, Sohaib A, Huddart RA, Dearnaley DP, Horwich A, Chua S.

Nucl Med Commun. 2015 Jul;36(7):702-8. doi: 10.1097/MNM.0000000000000303.

PMID:
25757201
12.
13.

Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.

Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD, Bares R, Kanz L.

Br J Cancer. 2002 Feb 12;86(4):506-11.

14.

18F-FDG PET/CT impact on testicular tumours clinical management.

Ambrosini V, Zucchini G, Nicolini S, Berselli A, Nanni C, Allegri V, Martoni A, Rubello D, Cricca A, Fanti S.

Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):668-73. doi: 10.1007/s00259-013-2624-3. Epub 2013 Nov 22. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):585. Domenico, Rubello [corrected to Rubello, Domenico].

PMID:
24265073
15.

[Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].

Müller-Mattheis V, Reinhardt M, Gerharz CD, Fürst G, Vosberg H, Müller-Gärtner HW, Ackermann R.

Urologe A. 1998 Nov;37(6):609-20. German.

PMID:
9887489
16.

FDG PET for detection and therapy control of metastatic germ cell tumor.

Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, Jakse G, Buell U.

J Nucl Med. 1998 May;39(5):815-22.

17.

Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital.

Lewis DA, Tann M, Kesler K, McCool A, Foster RS, Einhorn LH.

J Clin Oncol. 2006 Dec 1;24(34):e54-5. No abstract available.

PMID:
17135635
18.

False-positive finding in FDG-PET in a patient with seminoma and sarcoidosis.

Liepe K.

Acta Clin Belg. 2015 Apr;70(2):138-40. doi: 10.1179/2295333714Y.0000000099. Epub 2014 Nov 20.

PMID:
25409626
19.

[Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].

Pfannenberg AC, Oechsle K, Kollmannsberger C, Dohmen BM, Bokemeyer C, Bares R, Vontheim R, Claussen CD.

Rofo. 2004 Jan;176(1):76-84. German.

PMID:
14712410
20.

False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses.

Wagner M, Bellmunt J, Boutros C, Bonardel G, Loriot Y, Albiges L, Massard C, Fizazi K.

Clin Genitourin Cancer. 2013 Mar;11(1):66-9. doi: 10.1016/j.clgc.2012.06.006. Epub 2012 Sep 13. No abstract available.

PMID:
22981209

Supplemental Content

Support Center